KSPM
Search
- Page Path
- HOME > Search
Brief Report
- National Trends in Smoking Cessation Medication Prescriptions for Smokers With Chronic Obstructive Pulmonary Disease in the United States, 2007-2012
- Min Ji Kwak, Jongoh Kim, Viraj Bhise, Tong Han Chung, Gabriela Sanchez Petitto
- J Prev Med Public Health. 2018;51(5):257-262. Published online August 23, 2018
- DOI: https://doi.org/10.3961/jpmph.18.119
- 5,910 View
- 153 Download
- 7 Crossref
-
Abstract
PDF - Objectives
Smoking cessation decreases morbidity and mortality due to chronic obstructive pulmonary disease (COPD). Pharmacotherapy for smoking cessation is highly effective. However, the optimal prescription rate of smoking cessation medications among smokers with COPD has not been systemically studied. The purpose of this study was to estimate the national prescription rates of smoking cessation medications among smokers with COPD and to examine any disparities therein.
Methods
We conducted a retrospective study using National Ambulatory Medical Care Survey data from 2007 to 2012. We estimated the national prescription rate for any smoking cessation medication (varenicline, bupropion, and nicotine replacement therapy) each year. Multiple survey logistic regression was performed to characterize the effects of demographic variables and comorbidities on prescriptions.
Results
The average prescription rate of any smoking cessation medication over 5 years was 3.64%. The prescription rate declined each year, except for a slight increase in 2012: 9.91% in 2007, 4.47% in 2008, 2.42% in 2009, 1.88% in 2010, 1.46% in 2011, and 3.67% in 2012. Hispanic race and depression were associated with higher prescription rates (odds ratio [OR], 5.15; 95% confidence interval [CI], 1.59 to 16.67 and OR, 2.64; 95% CI, 1.26 to 5.51, respectively). There were no significant differences according to insurance, location of the physician, or other comorbidities. The high OR among Hispanic population and those with depression was driven by the high prescription rate of bupropion.
Conclusions
The prescription rate of smoking cessation medications among smokers with COPD remained low throughout the study period. Further studies are necessary to identify barriers and to develop strategies to overcome them. -
Summary
Citations
Citations to this article as recorded by
- Cigarette Smoking and Psychiatric Illness Among Individuals with COPD: a Systematic Review
Jacob Levin, David Estey, Ester Yadgaran, Esther Perez, Isabella Plotnick, Jennifer Gittleman, Joseph Friedman, Silvana Agterberg, Sylvie Messer, Tyler Pia, Jennifer Birchwale, Joun Lee, Lisa N. Cruz, Natacha A. Gordon, Rachel S. Kashan, Jung-Yun Min, Kat
Current Addiction Reports.2024; 11(1): 19. CrossRef - Challenges and perspectives of tobacco cessation in special groups of patients and populations
Stamatoula Tsikrika, Siyu Dai, Asli Dilektasli, Paraskevi Katsaounou, Elif Dagli
Breathe.2023; 19(2): 220224. CrossRef - Influence of ethnicity on adherence to nonsurgical interventions for COPD: a scoping review
Sarah Alamer, Anna Robinson-Barella, Hamde Nazar, Andy Husband
ERJ Open Research.2023; 9(6): 00421-2023. CrossRef - How the National Ambulatory Medical Care Survey has been used to identify health disparities in the care of patients in the United States
Amanda S. Weissman, Varun Ranpariya, Alan B. Fleischer, Steven R. Feldman
Journal of the National Medical Association.2021; 113(5): 504. CrossRef - Polypharmacy among Older Individuals with COPD: Trends between 2000 and 2015 in Quebec, Canada
Caroline Sirois, Amina Ouali, Marc Simard
COPD: Journal of Chronic Obstructive Pulmonary Disease.2019; 16(3-4): 234. CrossRef - Tobacco Screening and Treatment of Patients With a Psychiatric Diagnosis, 2012–2015
Erin S. Rogers, Christina N. Wysota
American Journal of Preventive Medicine.2019; 57(5): 687. CrossRef - Secular trends in smoking in relation to prevalent and
incident smoking-related disease: A prospective population-based
study
Philip Tonnesen, Jacob Marott, Børge Nordestgaard, S. Bojesen, Peter Lange
Tobacco Induced Diseases.2019;[Epub] CrossRef
First
Prev
